WASHINGTON DC -- (MARKET WIRE) -- 06/11/2006 -- Entelos, Inc. (LSE: ENTL) announced today that it presented data in a poster session at the 66th Annual American Diabetes Association Meeting. This presentation revealed the first-ever mathematical means for predicting not only the amount of weight gain expected for patients receiving type 2 diabetes treatments -- a common side effect -- but also the decrease in food intake necessary to prevent it (poster #564P). Such information can help doctors counsel type 2 diabetes patients on ways to minimize weight gain during treatment, which should enhance drug efficacy and improve their control of blood sugar levels.
